GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (LTS:0RBP) » Definitions » Gross Profit

Kiadis Pharma NV (LTS:0RBP) Gross Profit : €17.50 Mil (TTM As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Gross Profit?

Kiadis Pharma NV's gross profit for the six months ended in Dec. 2020 was €17.50 Mil. Kiadis Pharma NV's gross profit for the trailing twelve months (TTM) ended in Dec. 2020 was €17.50 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Kiadis Pharma NV's gross profit for the six months ended in Dec. 2020 was €17.50 Mil. Kiadis Pharma NV's Revenue for the six months ended in Dec. 2020 was €17.50 Mil. Therefore, Kiadis Pharma NV's Gross Margin % for the quarter that ended in Dec. 2020 was N/A%.

Kiadis Pharma NV had a gross margin of N/A% for the quarter that ended in Dec. 2020 => No sustainable competitive advantage


Kiadis Pharma NV Gross Profit Historical Data

The historical data trend for Kiadis Pharma NV's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Gross Profit Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Gross Profit
Get a 7-Day Free Trial Premium Member Only - - - - 17.50

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 17.50

Competitive Comparison of Kiadis Pharma NV's Gross Profit

For the Biotechnology subindustry, Kiadis Pharma NV's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Gross Profit distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Gross Profit falls into.



Kiadis Pharma NV Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Kiadis Pharma NV's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as

Gross Profit (A: Dec. 2020 )=Revenue - Cost of Goods Sold
=17.5 - 0
=17.50

Kiadis Pharma NV's Gross Profit for the quarter that ended in Dec. 2020 is calculated as

Gross Profit (Q: Dec. 2020 )=Revenue - Cost of Goods Sold
=17.5 - 0
=17.50

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2020 adds up the semi-annually data reported by the company within the most recent 12 months, which was €17.50 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Kiadis Pharma NV's Gross Margin % for the quarter that ended in Dec. 2020 is calculated as

Gross Margin % (Q: Dec. 2020 )=Gross Profit (Q: Dec. 2020 ) / Revenue (Q: Dec. 2020 )
=(Revenue - Cost of Goods Sold) / Revenue
=17.50 / 17.5
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Kiadis Pharma NV  (LTS:0RBP) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Kiadis Pharma NV had a gross margin of N/A% for the quarter that ended in Dec. 2020 => No sustainable competitive advantage


Kiadis Pharma NV Gross Profit Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (LTS:0RBP) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (LTS:0RBP) Headlines

No Headlines